A “Trading Update - FY22 in line with expectations”-titled announcement from tissue converter group Accrol (ACRL) sounds good given the current macro climate. So what of a current 26p share price?...
Previously writing on “the UK's leading independent tissue converter” Accrol (ACRL), last week with the shares falling to 25p I noted a further profit warning and a “strategic review” despite it arguing ‘timing issues’ and asked why no balance sheet numbers?. Now half-year results...
Previously writing on “the UK's leading independent tissue converter” Accrol (ACRL) in October with the shares falling below 40p, I concluded that the group argues the latest are “short-term external challenges”, but also raw material supply chains “further tightening in recent weeks”. As such, hopefully the prior warning was heeded and the stance remains avoid. Today a further trading update and the shares... further down to 25p. So what’s the latest?...
In May I concluded with shares in “the UK's leading independent tissue converter” Accrol (ACRL) lower at 54p to avoid as inflationary pressures could persist for some time given the wide pandemic response. The shares last closed at 44.95p and are currently below 40p on the back of a trading update...
Hello, Share Hawkers. There haven't been many humorous aspects to the pandemic. But we did have the hilarious sight of some shoppers staggering from supermarkets under the weight of extra toilet rolls. This madness helped loo-roll maker Accrol (ACRL) see a huge leap in income at the start of the pestilence. Up by 40%, it’s thought.
